BioSight
Companies
Candel Therapeutics, Inc. logo

CADL

NASDAQNEEDHAM, MA
Candel Therapeutics, Inc.

Candel Therapeutics is a clinical-stage biotech company developing gene therapy and other product candidates for treating disease, with programs including aglatimagene besadenovec and linoserpaturev currently in preclinical or early clinical testing. The company is focused on advancing these candidates through clinical trials with the goal of eventually generating revenue from approved products.

Price history not yet available for CADL.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar